CHI3L1 signaling impairs hippocampal neurogenesis and cognitive function in autoimmune-mediated neuroinflammation

Chitinase-3-like protein 1 (CHI3L1) is primarily secreted by activated astrocytes in the brain and is known as a reliable biomarker for inflammatory central nervous system (CNS) conditions such as neurodegeneration and autoimmune disorders like neuromyelitis optica (NMO). NMO is an astrocyte disease caused by autoantibodies targeting the astroglial protein aquaporin 4 (AQP4) and leads to vision loss, motor deficits, and cognitive decline. In this study examining CHI3L1's biological function in neuroinflammation, we found that CHI3L1 expression correlates with cognitive impairment in our NMO patient cohort. Activated astrocytes secrete CHI3L1 in response to AQP4 autoantibodies, and this inhibits the proliferation and neuronal differentiation of neural stem cells. Mouse models showed decreased hippocampal neurogenesis and impaired learning behaviors, which could be rescued by depleting CHI3L1 in astrocytes. The molecular mechanism involves CHI3L1 engaging the CRTH2 receptor and dampening beta-catenin signaling for neurogenesis. Blocking this CHI3L1/CRTH2/beta-catenin cascade restores neurogenesis and improves cognitive deficits, suggesting the potential for therapeutic development in neuroinflammatory disorders.

Automated summary

Chitinase-3-like protein 1 (CHI3L1) is a reliable biomarker for inflammatory central nervous system (CNS) conditions and is associated with neurodegeneration and autoimmune disorders. This study found that elevated CHI3L1 expression correlates with cognitive impairment in patients with neuromyelitis optica (NMO). CHI3L1 inhibits the proliferation and neuronal differentiation of neural stem cells, leading to decreased hippocampal neurogenesis and impaired learning behaviors. Blocking the CHI3L1/CRTH2/beta-catenin cascade restores neurogenesis and improves cognitive deficits, suggesting potential therapeutic development in neuroinflammatory disorders.